Skip to main content

Table 1 Clinical and pathological characteristics of patient population

From: Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients

  

n (%)

No. of patients

 

45 (100)

Gender; Median age (Min - Max), yrs

Female

24 (53.3); 54 (34 - 76)

 

Male

21 (46.7); 61 (35 - 75)

ECOG

0

20 (44.4)

 

≥ 1

25 (55.6)

Tumor Location

Esophageal

4 (8.9)

 

Gastric

19 (42.2)

 

Colorectal

22 (48.9)

TNM Stage

II

3 (6.7)

 

III

12 (26.7)

 

IV

30 (66.7)

Treatment Purpose

Adjuvant

14 (31.1)

 

Palliative

31 (68.9)

Chemotherapy Scheme

5-FU/Cisplatinum

23 (51.1)

 

Other*

22 (48.9)

5FU

Mode of Administration

Bolus alone

15 (33.3)

 

Bolus + CI#

8 (17.8)

 

Continuous infusion

22 (48.9)

  1. *5-FU/LV or 5-FU/FA or FolFOx or FolFIri; #Continous Infusion